Changes in circulating TCF1- and GARP-associated regulatory T cell subsets reflect the clinical status of patients with chronic HBV infection

Bahabayi, Ayibaota; Zeng, Xingyue; Tuerhanbayi, Bulidierxin; Zhang, Yangyang; Hasimu, Ainizati; Guo, Sheng; Liu, Tianci; Zheng, Mohan; Alimu, Xiayidan; Liu, Chen

doi:10.1007/s00430-022-00748-3

Cited by 5 publications

(5 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…IL-10, a pleiotropic cytokine with anti-inflammatory functions, acts as a negative regulator of the immune response. In fact, IL-10, including IL-10 produced by Tr1 cells, has been involved in the anti-inflammatory function in autoimmunity, viral/bacterial infections, and allograft transplantation [ 36 , 37 , 38 , 39 , 40 , 41 , 42 ]. Alterations in IL-10 producing Tr1 cells were shown to regulate multiple sclerosis, type 1 diabetes, and long-term allograft survival [ 43 , 44 , 45 ].…”

Section: Discussionmentioning

confidence: 99%

Differences in Responses of Immunosuppressed Kidney Transplant Patients to Moderna mRNA-1273 versus Pfizer-BioNTech

Bekbolsynov,

Waack,

Buskey

et al. 2024

Vaccines

View full text Add to dashboard Cite

Immunosuppressed kidney transplant (KT) recipients produce a weaker response to COVID-19 vaccination than immunocompetent individuals. We tested antiviral IgG response in 99 KT recipients and 66 healthy volunteers who were vaccinated with mRNA-1273 Moderna or BNT162b2 Pfizer-BioNTech vaccines. A subgroup of participants had their peripheral blood leukocytes (PBLs) evaluated for the frequency of T helper 1 (Th1) cells producing IL-2, IFN-γ and/or TNF-α, and IL-10-producing T-regulatory 1 (Tr) cells. Among KT recipients, 45.8% had anti-SARS-CoV-2 IgG compared to 74.1% of healthy volunteers (p = 0.009); also, anti-viral IgG levels were lower in recipients than in volunteers (p = 0.001). In terms of non-responders (≤2000 U/mL IgG), Moderna’s group had 10.8% and Pfizer-BioNTech’s group had 34.3% of non-responders at 6 months (p = 0.023); similarly, 15.7% and 31.3% were non-responders in Moderna and Pfizer-BioNTech groups at 12 months, respectively (p = 0.067). There were no non-responders among controls. Healthy volunteers had higher Th1 levels than KT recipients, while Moderna produced a higher Th1 response than Pfizer-BioNTech. In contrast, the Pfizer-BioNTech vaccine induced a higher Tr1 response than the Moderna vaccine (p < 0.05); overall, IgG levels correlated with Th1(fTTNF-α)/Tr1(fTIL-10) ratios. We propose that the higher number of non-responders in the Pfizer-BioNTech group than the Moderna group was caused by a more potent activity of regulatory Tr1 cells in KT recipients vaccinated with the Pfizer-BioNTech vaccine.

show abstract

Section: Discussionmentioning

confidence: 99%

Differences in Responses of Immunosuppressed Kidney Transplant Patients to Moderna mRNA-1273 versus Pfizer-BioNTech

Bekbolsynov,

Waack,

Buskey

et al. 2024

Vaccines

View full text Add to dashboard Cite

show abstract

“…IL-10, a pleiotropic cytokine with anti-inflammatory functions, acts as a negative regulator of the immune response. In fact, IL-10, including IL-10-produced by Tr1 cells, has been involved in antiinflammatory function in autoimmunity, viral/bacterial infections, and allograft transplantation [34][35][36][37][38][39][40]. Alterations in IL-10 producing Tr1 cells was shown to regulate multiple sclerosis, type 1 diabetes, and long-term allograft survival [41][42][43].…”

Section: Discussionmentioning

confidence: 99%

Differences in Response by Immunosuppressed Kidney Transplant Patients to Moderna mRNA-1273 versus Pfizer-BioNTech

Bekbolsynov,

Waack,

Buskey

et al. 2023

Preprint

View full text Add to dashboard Cite

Immunosuppressed kidney transplant (KT) recipients respond weaker to COVID-19 vaccination than immunocompetent individuals. We tested antiviral IgG response in 99 KT-recipients and 66 healthy volunteers who were vaccinated with mRNA-1273 Moderna or BNT162b2 Pfizer-BioNTech vaccines. A subgroup of participants had their peripheral blood leukocytes (PBLs) evaluated for the frequency of T helper 1 (Th1) cells producing IL-2, IFN-γ and/or TNF-α, and IL-10-producing T-regulatory 1 (Tr) cells. Among KT-recipients, 45.8% had anti-SARS-CoV-2 IgG compared to 74.1% of healthy volunteers (p=0.009); also, anti-viral IgG levels were lower in recipients than in volunteers (p=0.001). When defined as non-responders (≤2,000 U/ml IgG), Moderna’s group had 10.8% and Pfizer-BioNTech’s group had 34.3% of non-responders at 6 months (p=0.023); similarly, 15.7% and 31.3% non-responders were in Moderna and Pfizer-BioNTech groups at 12 months, respectively (p=0.067). There were no non-responders among controls. Healthy volunteers had higher Th1 levels than KT recipients, while Moderna produced higher Th1 response than Pfizer-BioNTech. In contrast, Pfizer-BioNTech vaccine induced higher Tr1 response than Moderna vaccine (p&lt;0.05); overall, IgG levels correlated with Th1(fTTNF-α)/Tr1(fTIL-10) ratios. We propose that the higher number of non-responders in Pfizer-BioNTech group than Moderna group was caused by more potent activity of regulatory Tr1 cells in KT-recipients vaccinated with Pfizer-BioNTech vaccine.

show abstract

“…Increased TFR cells and decreased IL-21 levels promote the differentiation of Breg cells in patients with CHB and suppress plasmablast differentiation and IFN-γ from CD8 + T cells ( Wang et al., 2018a ). The expression of GARP and Tcf-1 in Tregs and TFR cells is upregulated in patients with CHB, and Tcf-1, CD62L, and GARP-classified Treg and TFR subsets are altered ( Bahabayi et al., 2022 ).…”

Section: Inhibitory Cells In Immune Responsementioning

confidence: 99%

Immune response and treatment targets of chronic hepatitis B virus infection: innate and adaptive immunity

Zheng

Dou

Wang

2023

Front. Cell. Infect. Microbiol.

View full text Add to dashboard Cite

Chronic hepatitis B virus (HBV) infection is a major global public health risk that threatens human life and health, although the number of vaccinated people has increased. The clinical outcome of HBV infection depends on the complex interplay between viral replication and the host immune response. Innate immunity plays an important role in the early stages of the disease but retains no long-term immune memory. However, HBV evades detection by the host innate immune system through stealth. Therefore, adaptive immunity involving T and B cells is crucial for controlling and clearing HBV infections that lead to liver inflammation and damage. The persistence of HBV leads to immune tolerance owing to immune cell dysfunction, T cell exhaustion, and an increase in suppressor cells and cytokines. Although significant progress has been made in HBV treatment in recent years, the balance between immune tolerance, immune activation, inflammation, and fibrosis in chronic hepatitis B remains unknown, making a functional cure difficult to achieve. Therefore, this review focuses on the important cells involved in the innate and adaptive immunity of chronic hepatitis B that target the host immune system and identifies treatment strategies.

show abstract

Changes in circulating TCF1- and GARP-associated regulatory T cell subsets reflect the clinical status of patients with chronic HBV infection

Cited by 5 publications

References 34 publications

Differences in Responses of Immunosuppressed Kidney Transplant Patients to Moderna mRNA-1273 versus Pfizer-BioNTech

Differences in Responses of Immunosuppressed Kidney Transplant Patients to Moderna mRNA-1273 versus Pfizer-BioNTech

Differences in Response by Immunosuppressed Kidney Transplant Patients to Moderna mRNA-1273 versus Pfizer-BioNTech

Immune response and treatment targets of chronic hepatitis B virus infection: innate and adaptive immunity

Contact Info

Product

Resources

About